Neuren Pharmaceuticals Ltd (ASX: NEU) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Neuren Pharmaceuticals Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Neuren Pharmaceuticals Ltd (ASX: NEU)
Latest News
Investing Strategies
Top-performing ASX 200 shares of 2023 without stomach-churning volatility
Share Market News
Best ASX 200 shares vs. best suburbs for property investment in 2023
Best Shares
5 best performing ASX All Ords shares of 2023
Share Market News
ASX 200 shares vs. property: Which delivered the best growth in 2023?
Share Gainers
Can you guess which were the best-performing ASX 200 shares in 2023?
Investing Strategies
Could investing $10,000 in this ASX 200 share make you a millionaire?
Broker Notes
Top brokers name 3 ASX shares to buy next week
Share Gainers
Why Boss Energy, Lynas, Neuren, and Ora Banda shares are rising today
Share Fallers
Why Atlantic Lithium, KMD Brands, Neuren, and PEXA shares are falling today
Broker Notes
Top brokers name 3 ASX shares to buy today
Investing Strategies
Could buying this ASX 200 stock at $23 be like investing in Amazon in 2008?
Share Gainers
Why G8 Education, Lake Resources, Liontown, and Neuren shares are racing higher
Frequently Asked Questions
-
No, Neuren Pharmaceuticals does not pay dividends at this time.
-
Neuren Pharmaceuticals Limited (ASX: NEU) listed on the ASX on 3 February 2005.
NEU ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Neuren Pharmaceuticals Ltd
Neuren Pharmaceuticals Limited (ASX: NEU) is a biopharmaceutical company specialising in developing new therapies for neurodevelopmental disorders that emerge in early childhood and are characterised by impaired connections and signalling between brain cells.
In March 2023, the US Food and Drug Administration approved DAYBUE™ (trofinetide) for the treatment of Rett syndrome in adults and children two years and older. Neuren's US partner Acadia Pharmaceuticals (NASDAQ: ACAD) holds a worldwide exclusive licence from Neuren for trofinetide. At this time, DAYBUE is the first and only drug approved for the treatment of Rett syndrome. Trofinetide has also demonstrated clinical benefit in a Phase 2 trial in treating Fragile X syndrome.
Neuren's second product NNZ-2591 is currently in Phase 2 clinical trials for the treatment of Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome, and Prader-Willi syndrome. The drug candidate has shown positive effects in mouse models of each syndrome and was successful in a Phase 1 clinical trial. The number of patients across these four disorders is estimated as five times the number of Rett syndrome patients. There are currently no drugs approved for these conditions, apart from growth hormone to treat some aspects of Prader-Willi.
Acadia Pharmaceuticals also holds a worldwide exclusive licence to develop and commercialise NNZ-2591 for Rett syndrome and Fragile X syndrome. Neuren retains worldwide rights to NNZ-2591 in all other indications.
NEU Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 30 Apr 2026 | $12.46 | $0.19 | 1.55% | 321,185 | $12.12 | $12.66 | $11.98 |
| 29 Apr 2026 | $12.27 | $0.34 | 2.85% | 299,700 | $11.94 | $12.42 | $11.84 |
| 28 Apr 2026 | $11.93 | $-0.27 | -2.21% | 347,557 | $12.08 | $12.12 | $11.68 |
| 27 Apr 2026 | $12.20 | $-0.13 | -1.05% | 170,555 | $12.33 | $12.39 | $12.08 |
| 24 Apr 2026 | $12.33 | $0.15 | 1.23% | 283,618 | $12.15 | $12.33 | $12.01 |
| 23 Apr 2026 | $12.18 | $0.04 | 0.33% | 312,591 | $12.00 | $12.43 | $11.91 |
| 22 Apr 2026 | $12.14 | $-0.31 | -2.49% | 237,860 | $12.40 | $12.40 | $12.12 |
| 21 Apr 2026 | $12.45 | $-0.03 | -0.24% | 213,023 | $12.56 | $12.64 | $12.37 |
| 20 Apr 2026 | $12.48 | $-0.01 | -0.08% | 202,141 | $12.64 | $12.77 | $12.45 |
| 17 Apr 2026 | $12.49 | $0.01 | 0.08% | 254,622 | $12.34 | $12.52 | $12.33 |
| 16 Apr 2026 | $12.48 | $-0.01 | -0.08% | 285,507 | $12.65 | $12.66 | $12.33 |
| 15 Apr 2026 | $12.49 | $0.13 | 1.05% | 414,922 | $12.42 | $12.71 | $12.39 |
| 14 Apr 2026 | $12.36 | $0.13 | 1.06% | 277,046 | $12.51 | $12.67 | $12.34 |
| 13 Apr 2026 | $12.23 | $-0.29 | -2.32% | 206,401 | $12.25 | $12.35 | $12.01 |
| 10 Apr 2026 | $12.52 | $-0.06 | -0.48% | 247,703 | $12.30 | $12.61 | $12.28 |
| 09 Apr 2026 | $12.58 | $-0.42 | -3.23% | 252,921 | $12.70 | $12.89 | $12.49 |
| 08 Apr 2026 | $13.00 | $0.70 | 5.69% | 489,697 | $12.73 | $13.22 | $12.73 |
| 07 Apr 2026 | $12.30 | $0.27 | 2.24% | 247,337 | $12.25 | $12.58 | $12.07 |
| 02 Apr 2026 | $12.03 | $-0.31 | -2.51% | 436,301 | $12.38 | $12.40 | $11.83 |
| 01 Apr 2026 | $12.34 | $0.53 | 4.49% | 482,680 | $12.04 | $12.35 | $11.99 |
| 31 Mar 2026 | $11.81 | $0.18 | 1.55% | 518,165 | $11.37 | $12.08 | $11.24 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 05 Mar 2026 | Joseph(Joe) Basile | Buy | 12,300 | $151,782 |
On-market trade.
|
| 08 Sep 2025 | Jonathan (Jon) Pilcher | Sell | 398,207 | $7,964,140 |
On-market trade.
|
| 22 Jul 2025 | Jonathan (Jon) Pilcher | Exercise | 1,500,000 | $2,760,000 |
Conversion of securities. Repayment of loan for 1,500,000 Loan Funded Shares
previously held in trust by Neuren Trustee Limited, at $1.84 per share and conversion to Ordinary Shares. |
| 22 Jul 2025 | Jonathan (Jon) Pilcher | Buy | 1,500,000 | $2,760,000 |
Conversion of securities. Repayment of loan for 1,500,000 Loan Funded Shares
previously held in trust by Neuren Trustee Limited, at $1.84 per share and conversion to Ordinary Shares. |
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Ms Dianne Margaret Angus | Non-Executive Director | Jul 2018 |
Ms Angus has executive managerial and company director experience in the biotechnology, biopharmaceutical, medical device, agritech and healthcare industries. She has created numerous global industry partnerships to yield innovative and competitive medical, pharmaceutical and agricultural products. With over twenty five years' experience in ASX and NASDAQ listed companies, she has expertise in business development, capital raising and investor relations together with corporate governance and compliance capabilities.
|
| Mr Jonathan (Jon) Charles Pilcher | Chief Executive OfficerManaging Director | Aug 2013 |
Mr Pilcher has played a central role in all aspects of the company's R&D, commercial and corporate activities. He formerly spent seven years in a series of executive positions in the R&D and corporate functions of international pharmaceutical groups Medeva and Celltech, which are now part of UCB.
|
| Dr Jenny Lee Harry | Non-Executive Director | Jul 2018 |
Dr Harry has experience in executive management of companies in the biotechnology and biopharmaceutical industry and is an accomplished CEO and Managing Director with experience in early-stage companies to develop and commercialise innovative products. She has served on Boards of a number of listed and unlisted companies.
|
| Mr Patrick Davies | Non-Executive DirectorNon-Executive Chairman | Jul 2018 |
Mr Davies held executive management roles in the Australian and New Zealand healthcare industry for over twenty five years having performed in senior roles across many industry sectors including pharmacy, primary care, pharmaceutical and consumer products. He is a director on other corporate boards and provides strategic advice to a range of healthcare businesses and investors.
|
| Mr Joseph(Joe) Basile | Non-Executive Director | Mar 2023 |
Mr Basile has held a number of executive roles in the pharmaceutical industry for over 30 years, recently as Group CFO at iNova Pharmaceuticals based in Singapore and prior to that with Novartis in senior Finance leadership and Commercial Sales leadership roles in Australia and Asia.
|
| Ms Lauren Frazer | Chief Financial OfficerCompany Secretary | Aug 2020 |
-
|
| Gerry Zhao | Chief Business Officer |
-
|
|
| Lauren Frazer | Chief Financial OfficerCompany Secretary |
-
|
|
| Liza Squires | Chief Medical Officer |
-
|
|
| Clive Blower | Chief Operations Officer |
-
|
|
| Daryl Dekarske | Chief Regulatory Officer |
-
|
|
| Larry Glass | Chief Science Officer |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Hsbc Custody Nominees (Australia) Limited | 22,145,477 | 17.50% |
| Citicorp Nominees Pty Limited | 13,834,099 | 10.93% |
| J P Morgan Nominees Australia Pty Limited | 10,413,515 | 8.23% |
| BNP Paribas Noms Pty Ltd | 5,238,479 | 4.14% |
| Cameron Richard Pty Ltd | 3,914,900 | 3.09% |
| Stuart Andrew Pty Ltd | 2,814,100 | 2.22% |
| Smithley Super Pty Ltd | 1,577,000 | 1.25% |
| Linwierik Super Pty Ltd | 1,560,000 | 1.23% |
| BNP Paribas Nominees Pty Ltd (i) | 1,520,378 | 1.20% |
| Jonathan Pilcher | 1,500,000 | 1.19% |
| Sharesies Australia Nominee Pty Limited | 1,323,965 | 1.05% |
| Southern Capital Limited | 1,103,947 | 0.87% |
| Mjhft Pty Ltd | 900,000 | 0.71% |
| Essex Castle Limited | 843,731 | 0.67% |
| First Colbyco Pty Ltd | 800,000 | 0.63% |
| BNP Paribas Nominees Pty Ltd | 714,490 | 0.56% |
| Dr Robin Lance Congreve | 641,637 | 0.51% |
| Emancipayte Pty Ltd | 463,151 | 0.37% |
| BNP Paribas Nominees Pty Ltd (ii) | 463,066 | 0.37% |
| Mr He Zhao | 424,600 | 0.34% |
